Differences in nephrotoxicity risk and renal effects among anti-viral therapies against hepatitis B

Basit Öğe Kaydı
dc.contributor.authorKoklu, S.
dc.contributor.authorGulsen, M. T.
dc.contributor.authorTuna, Y.
dc.contributor.authorKoklu, H.
dc.contributor.authorYuksel, O.
dc.contributor.authorDemir, M.
dc.contributor.authorGuner, R.
dc.date.accessioned2024-02-23T14:24:02Z
dc.date.available2024-02-23T14:24:02Z
dc.date.issued2015
dc.departmentNEÜen_US
dc.description.abstractBackgroundResults are conflicting with respect to the renal effects of anti-viral agents used for hepatitis B virus infection. AimTo compare short and long-term renal effects in real-life settings and to determine risk factors for renal impairment during treatment. Methods2221 treatment-naive patients were enrolled. Among these, 895 (302 lamivudine, 27 telbivudine, 282 entecavir, 273 tenofovir and 11 adefovir initiated patients) had repeated measures' of creatinine (baseline, 1st, 6th, 12th and 24th month of treatment). Telbivudine and adefovir groups were excluded from further analysis because of the low number of patients. We calculated the glomerular filtration rate (GFR) using the Modification of Diet in Renal Disease (MDRD) formula at each time point. Hypophosphataemia was also recorded. Risk factors for renal impairment were analysed. ResultsTenofovir caused a decline in GFR at each time point when compared to baseline levels. However, lamivudine and entecavir did not change GFR. GFR-shifting from 90 to 60-89mL/min/1.73m(2) was comparable among groups. The proportion of patients whose baseline creatinine increased more than 25% was comparable among all anti-virals. GFR showed a decline in patients who switched from entecavir to tenofovir. One patient with compensated cirrhosis needed to change from tenofovir because of renal safety. Seven and three patients developed transient hypophosphataemia in the tenofovir and lamivudine groups, respectively. ConclusionsAlthough tenofovir caused a decline in GFR, differences between the anti-viral agents do not appear to be so impressive. In patients with and without renal risk factors at baseline, there is no impact of anti-virals, including tenofovir.en_US
dc.identifier.doi10.1111/apt.13036
dc.identifier.endpage319en_US
dc.identifier.issn0269-2813
dc.identifier.issn1365-2036
dc.identifier.issue3en_US
dc.identifier.pmid25982037en_US
dc.identifier.scopus2-s2.0-84920729292en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage310en_US
dc.identifier.urihttps://doi.org/10.1111/apt.13036
dc.identifier.urihttps://hdl.handle.net/20.500.12452/13792
dc.identifier.volume41en_US
dc.identifier.wosWOS:000347835300007en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWiley-Blackwellen_US
dc.relation.ispartofAlimentary Pharmacology & Therapeuticsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subject[Keyword Not Available]en_US
dc.titleDifferences in nephrotoxicity risk and renal effects among anti-viral therapies against hepatitis Ben_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu